Guangdong Zhongsheng Pharmaceutical revises governance framework, abolishes board of supervisors

Guangdong Zhongsheng Pharmaceutical held board meetings on December 11, 2025, to approve significant updates to its governance documents. These changes, effective from their approval date, include amendments to the Articles of Association, leading to the abolishment of the board of supervisors and the transfer of its functions to the board of directors' audit committee.

The company also revised 32 existing governance systems and introduced two new ones to comply with regulatory adjustments and enhance internal operations. Key revisions include updates to the measures for the administration of related party transactions, the remuneration management system for directors, supervisors and senior management, and the major information internal reporting system. Additionally, the company approved a revised shareholder return plan for 2025-2027 and a new information disclosure exemption and deferral management system. These updates aim to improve corporate governance, streamline internal processes, and adapt to evolving regulatory policies.